trending Market Intelligence /marketintelligence/en/news-insights/trending/thotx-2xu8gzvqbqbd6yxg2 content esgSubNav
In This List

Teva denies pay-for-delay charges on Provigil generic

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Teva denies pay-for-delay charges on Provigil generic

Teva Pharmaceutical Industries Ltd. denied EU antitrust charges related to the delayed launch of a generic version of Cephalon Inc.'s sleep disorder drug Provigil, Reuters reported.

The European Commission's charges state that Teva was part of an unlawful deal with Cephalon to delay selling the generic version of Provigil, according to the news outlet.

The Israeli drugmaker made a deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the drug. As part of this agreement, Teva undertook not to sell its generic modafinil products in the European Economic Area until October 2012.

Teva later acquired Cephalon in 2011.

In a statement referring to the EU charge sheet, Teva said it had not entered into any anti-competitive behavior with Cephalon, Reuters reported.

In February 2017, Mylan NV agreed to pay $96.5 million to settle claims that it delayed launching a generic version of Provigil in exchange for payment from Cephalon.